Index,P,I,C,O,S,matches_criteria,reasoning
0,patients with unresectable or metastatic hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,"randomised, open-label, international phase 3 trial",True,matches all PICOS criteria
1,patients with advanced hepatocellular carcinoma,LEN plus on-demand TACE,LEN monotherapy,overall survival,"multicenter, randomized, open-label, parallel group, phase III trial",False,intervention does not match ICIs
2,patients with advanced hepatocellular carcinoma,nivolumab,sorafenib,overall survival,"randomised, open-label, phase 3 trial",True,matches all PICOS criteria
3,patients with unresectable hepatocellular carcinoma,FOLFOX-HAIC,TACE,overall survival,"randomized, multicenter, open-label trial",False,intervention does not match ICIs
4,patients with advanced HCC previously treated with a multityrosine kinase inhibitor,DNA plasmid PTCV plus pembrolizumab,not specified,"safety, immunogenicity, treatment efficacy, and feasibility","single-arm, open-label, phase 1/2 study",False,comparison not specified and study design not RCT
5,patients with locally advanced hepatocellular carcinoma,TACE and stereotactic body radiotherapy followed by avelumab,not specified,proportion of patients amenable to curative treatment,"single-arm, phase 2 trial",False,comparison not specified and study design not RCT
6,patients with intermediate-stage HCC,lenvatinib plus pembrolizumab plus TACE,placebos plus TACE,overall survival and progression-free survival,"prospective, double-blind randomized phase 3 study",True,matches all PICOS criteria
7,participants with intermediate-stage HCC,yttrium 90 glass TARE,doxorubicin drug-eluting bead TACE,time to overall tumor progression and overall survival,single-center prospective randomized controlled trial,False,intervention does not match ICIs
8,patients with HCC,anti-PD-1 monotherapy,not specified,early detection of HCC and early assessment for anti-PD-1 immunotherapy efficacy,not specified,False,comparison and study design not specified
9,patients with HCC,anti-PD-1 therapy,not specified,immune trajectories and mechanisms of response and/or irAEs,not specified,False,comparison and study design not specified
10,cancer patients with neurologic immune-related adverse events,anti-PD-1 or anti-PD-L1 monotherapy or combination therapy,cancer control patients without irAE-n,immune cell dysregulation and diagnostic markers,observational cohort study,False,Population does not match; study design is not RCT
11,patients with resectable hepatocellular carcinoma,camrelizumab plus apatinib,not specified,"pathological response, relapse-free survival, adverse events","open-label, single-arm, phase II clinical trial",False,Comparison not specified; study design is not RCT
12,patients with resectable hepatocellular carcinoma,neoadjuvant cemiplimab,not specified,"tumor necrosis, overall response, adverse events","single-arm, open-label, phase 2 trial",False,Comparison not specified; study design is not RCT
13,patients with unresectable hepatocellular carcinoma,lenvatinib plus anti-PD-1 antibodies,not specified,"conversion success rate, objective response rate, progression-free survival","single-arm, phase II study",False,Comparison not specified; study design is not RCT
14,patients with sorafenib-failed hepatocellular carcinoma,pembrolizumab,not specified,objective response rate,single-arm prospective phase II trial,False,Comparison not specified; study design is not RCT
15,patients with unresectable hepatocellular carcinoma,regorafenib-nivolumab,not specified,"objective response rate, progression-free survival, overall survival","multicenter, single-arm, phase 2 trial",False,Comparison not specified; study design is not RCT
16,patients with advanced hepatocellular carcinoma,nivolumab monotherapy,not specified,"objective response rate, overall survival",dose-escalation and dose-expansion phases,False,Comparison not specified; study design is not RCT
17,patients with resectable hepatocellular carcinoma,nivolumab with or without ipilimumab,nivolumab vs nivolumab plus ipilimumab,"safety, overall response, progression-free survival","single-centre, randomised, open-label, phase 2 trial",True,Matches all PICOS criteria
18,patients with unresectable hepatocellular carcinoma,tremelimumab in combination with durvalumab,not specified,"overall survival, adverse events",phase I/II and phase III studies,False,Comparison not specified; study design is not RCT
19,patients with early-stage resectable hepatocellular carcinoma,neoadjuvant PD-1 blockade plus stereotactic body radiotherapy,not specified,"tumor response, safety, tolerability",phase 1b trial,False,Comparison not specified; study design is not RCT
20,patients with HCC and MVI,adjuvant sintilimab,active surveillance,"recurrence-free survival, overall survival",randomized controlled trial,True,"Matches all PICOS criteria: population with HCC, intervention with ICI, comparison with no ICI, outcomes include survival rates, study design is RCT."
21,patients with locally advanced HCC,NK cell therapy plus HAIC,not specified,"safety, ORR, PFS, OS",phase I trial,False,"Does not match PICOS criteria: no comparison group specified, study design is not RCT."
22,patients with unresectable HCC,atezolizumab plus bevacizumab,not specified,"OS, PFS, ORR",observational study,False,"Does not match PICOS criteria: no comparison group specified, study design is not RCT."
23,patients with locally advanced unresectable HCC,Y90-radioembolization plus durvalumab,not specified,"TTP, OS, PFS, ORR",phase I/IIa pilot trial,False,"Does not match PICOS criteria: no comparison group specified, study design is not RCT."
24,patients with recurrent intermediate-stage HCC and MVI,SOR-TACE,TACE alone,"OS, PFS, ORR",randomized clinical trial,False,Does not match PICOS criteria: intervention is not ICI.
25,patients with localized early HCC,radiation therapy,not specified,"local control, adverse events, PFS",not specified,False,"Does not match PICOS criteria: intervention is not ICI, no comparison group specified, study design not specified."
26,patients with metastatic solid tumors including HCC,CD8 PET imaging,not specified,"safety, biodistribution of CD8+ leukocytes",phase 1 study,False,"Does not match PICOS criteria: intervention is not ICI, no comparison group specified, study design is not RCT."
27,patients with small HCC,laparoscopic liver resection,radiofrequency ablation,"OS, recurrence-free survival",randomized controlled trial,False,Does not match PICOS criteria: intervention is not ICI.
28,patients with advanced HCC,nivolumab plus ipilimumab,not specified,"ORR, DOR, OS",randomized study,False,Does not match PICOS criteria: no comparison group specified.
29,patients with unresectable HCC,SBRT,not specified,"PFS, ORR, OS",phase 2 nonrandomized controlled trial,False,"Does not match PICOS criteria: intervention is not ICI, no comparison group specified, study design is not RCT."
30,patients with intrahepatic cholangiocarcinoma,immune checkpoint blockades,not specified,prognostic significance of SPP1(+) TAMs,not specified,False,"Population is not hepatocellular carcinoma, and study design is not specified as randomized controlled trial."
31,patients with advanced stage hepatocellular carcinoma,"lenvatinib, sintilimab plus TACE",not specified,"progression-free survival, objective response rate",single-arm phase II trial,False,"Comparison is not specified, and study design is not randomized controlled trial."
32,patients with unresectable hepatocellular carcinoma,"STRIDE regimen, durvalumab",sorafenib,"patient-reported outcomes, time to deterioration",randomized controlled trial,True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design."
33,patients with hepatocellular carcinoma,2D and 3D CE US,CE MRI or CT,diagnostic performance in detecting residual viable HCC,prospective multicenter trial,False,"Intervention is not immune checkpoint inhibitors, and study design is not specified as randomized controlled trial."
34,patients with hepatocellular carcinoma with portal vein tumor thrombus,sorafenib plus transarterial chemoembolization,sorafenib alone,"recurrence-free survival, overall survival","phase 3, multicenter, randomized clinical trial",False,Intervention is not immune checkpoint inhibitors.
35,patients with hepatocellular carcinoma,proton beam radiotherapy,transarterial chemoembolization,"overall survival, progression-free survival",randomized,False,Intervention is not immune checkpoint inhibitors.
36,patients with hepatocellular carcinoma,DEB-TACE using small-size microspheres,not specified,6-month objective response rate,"prospective, single-arm, multicenter study",False,"Intervention is not immune checkpoint inhibitors, and study design is not randomized controlled trial."
37,patients with liver-confined hepatocellular carcinoma,TACE plus pembrolizumab,not specified,"progression-free survival, objective response rate",not specified,False,"Comparison is not specified, and study design is not specified as randomized controlled trial."
38,patients with very early- to intermediate-stage hepatocellular carcinoma,HepaVac-101 cancer vaccine,not specified,"safety, tolerability, antigen-specific T-cell responses","single-arm, first-in-human phase I/II multicenter trial",False,"Intervention is not immune checkpoint inhibitors, and study design is not randomized controlled trial."
39,patients with hepatocellular carcinoma,not specified,not specified,prognostic power in predicting patient survival,prospective cohort study,False,"Intervention and comparison are not specified, and study design is not randomized controlled trial."
40,patients with HCC,microwave ablation (MWA) and radiofrequency ablation (RFA),MWA vs RFA,"disease-free survival (DFS), overall survival (OS)",prospective trial,False,"Population matches, but intervention is not ICIs, and study design is not specified as randomized controlled trial."
41,patients with unresectable hepatocellular carcinoma,bavituximab plus pembrolizumab,not specified,"objective response rate, progression-free survival, overall survival",single-arm phase 2 trial,False,"Population and intervention match, but there is no comparison group and study design is not randomized controlled trial."
42,patients with unresectable HCC,selective internal radiation therapy (SIRT),not specified,"downstaging, overall survival","retrospective, observational study",False,"Population matches, but intervention is not ICIs, and study design is not randomized controlled trial."
43,patients with HCC eligible for TACE,TACE-DEB vs SBRT,TACE-DEB vs SBRT,"time to progression, overall survival, response rate",multicenter randomized trial,False,"Population matches, but intervention is not ICIs."
44,patients with unresectable HCC,TACE combined with envafolimab and lenvatinib,not specified,"objective response rate, progression-free survival",not specified,False,"Population and intervention partially match, but there is no comparison group and study design is not specified."
45,patients with intermediate/advanced HCC after curative resection,adjuvant immune checkpoint inhibitors (ICIs),with vs without adjuvant ICIs,"recurrence-free survival, overall survival",prospectively-collected multicenter database,True,"Population, intervention, comparison, and outcomes match PICOS criteria. Study design involves comparison but is not explicitly a randomized controlled trial."
46,patients with unresectable HCC and liver-only disease,SIRT followed by nivolumab,not specified,"objective response rate, time to progression, overall survival","single-arm, multicenter, open-label, phase 2 trial",False,"Population and intervention match, but there is no comparison group and study design is not randomized controlled trial."
47,"patients with a solitary HCC ≤8 cm, ineligible for surgical resection or transplantation",SABR vs other standard of care therapies,SABR vs thermal ablation or best standard of care therapy,"freedom from local progression, progression free survival, overall survival","phase II, prospective, randomised trial",False,"Population matches, but intervention is not ICIs."
48,patients with chronic hepatitis B and biopsy-proven histological significant fibrosis,entecavir-based therapy,not specified,"incidence of HCC, liver-related events",randomized controlled trial,False,"Population does not match, and intervention is not ICIs."
49,patients with HCC and Vp4 portal vein tumor thrombosis,irradiation stent placement with 125 I plus TACE vs sorafenib plus TACE,ISP-TACE vs Sora-TACE,"overall survival, hepatic function, time to symptomatic progression",multicenter randomized controlled trial,False,"Population matches, but intervention is not ICIs."
50,patients with recurrent or oligometastatic HCC,SBRT plus sintilimab,not specified,"progression-free survival, overall survival, response rate",not specified,False,"No comparison group specified, study design not clearly RCT"
51,patients with HCC,acyclic retinoid,not specified,"HCC recurrence, long-term prognosis",not specified,False,"Intervention not ICIs, no comparison group, study design not RCT"
52,patients with advanced HCC,sitravatinib with/without tislelizumab,not specified,objective response rate,phase Ib/II study,False,"No clear comparison group, study design not strictly RCT"
53,elderly patients with HCC,sorafenib or lenvatinib,not specified,"progression-free survival, overall survival",retrospective observational study,False,"Intervention not ICIs, no comparison group, study design not RCT"
54,systemic treatment-naive patients with uHCC,tislelizumab plus lenvatinib,historical control of lenvatinib monotherapy,"objective response rate, disease control rate, progression-free survival, overall survival","multicenter, single-arm, phase 2 study",False,"Study design not RCT, comparison is historical control"
55,patients with iuHCC,lenvatinib combined with TACE plus a PD-1 inhibitor,initial surgery,"event-free survival, overall survival",retrospective study,False,"Study design not RCT, intervention includes non-ICI components"
56,treatment-naive patients with resectable HCC with MVI,tislelizumab plus IMRT,not specified,"overall response rate, overall survival, recurrence-free survival",phase 2 trial,False,"No comparison group, study design not RCT"
57,"patients with single huge, resectable HCC","TACE, camrelizumab, and apatinib",surgery alone,recurrence-free survival,"multi-center, open-label randomized phase 3 trial",False,"Intervention includes non-ICI components, study design not strictly RCT"
58,HCC patients after narrow-margin hepatectomy,RT vs TACE,RT vs TACE,"overall survival, progression-free survival",single-center prospective randomized study,False,"Interventions not ICIs, study design not strictly RCT"
59,HCC and MT patients with 1.5-4 cm tumors,MWA vs RFA,MWA vs RFA,"short-to-long diameter ratio of ablation zone, local tumor progression",randomized phase 2 clinical trial,False,"Interventions not ICIs, study design not strictly RCT"
60,patients with recurrent hepatocellular carcinoma,radiofrequency ablation combined with toripalimab (anti-PD-1),RFA alone,recurrence free survival,randomized controlled trial,True,"Matches PICOS criteria with a clear population, intervention, comparison, outcome, and study design."
61,patients with HCC of BCLC stage A exceeding the Milan criteria or BCLC stage B,sintilimab plus DEB-TACE,not specified,"progression-free survival, objective response rate","prospective, phase II study",False,Lacks a specified comparison group and is not a randomized controlled trial.
62,patients with advanced hepatocellular carcinoma,radiotherapy combined with tislelizumab and anlotinib,not specified,"overall survival, progression-free survival",not specified,False,Lacks a specified comparison group and study design details.
63,patients with impaired liver function or tumors not amenable to thermal ablation,stereotactic body radiotherapy with dose optimization,conventional SBRT,"local control, toxicity",phase II clinical trial,False,Population and intervention do not match the target PICOS criteria.
64,HCC patients who underwent hepatectomy,postoperative adjuvant transarterial chemoembolization,no PA-TACE,"disease-free survival, overall survival",retrospective analysis,False,Study design is not a randomized controlled trial.
65,patients with early-stage hepatocellular carcinoma,machine learning model for treatment recommendations,not specified,survival rates,retrospective analysis,False,Intervention and study design do not match the target PICOS criteria.
66,patients with small malignant liver tumors,CEUS-CT/MRI fusion imaging guided RFA,B-mode US,"tumor visibility, technical success, local tumor progression",prospective study,False,Population and intervention do not match the target PICOS criteria.
67,BCLC early stage HCC patients with lesions 2-5 cm,adjuvant (super-)selective infusion of (166)Ho-MS after RFA,not specified,"target volume dose, local recurrences","multicenter, prospective dose-escalation study",False,Lacks a specified comparison group and is not a randomized controlled trial.
68,patients with unresectable HCC previously treated with systemic therapy,atezolizumab and bevacizumab,not specified,"overall survival, time-to-progression, progression-free survival",observational study,False,Lacks a specified comparison group and is not a randomized controlled trial.
69,"patients with poor prognosis, localized HCC",pembrolizumab with glass Y90 radioembolization,not specified,"progression-free survival, overall survival","open-label, single-arm multicenter, pilot study",False,Lacks a specified comparison group and is not a randomized controlled trial.
70,patients with intermediate-stage HCC,atezolizumab + bevacizumab prior to or in combination with TACE,not specified,"24-month survival rate, objective response rate, progression-free survival, safety, quality of life","multicenter, randomized phase II study",True,"Matches PICOS criteria: population, intervention, outcome, and study design align with target criteria. Comparison is not specified."
71,"patients with locally advanced, metastatic or unresectable HCC",atezolizumab and bevacizumab combined with UCPVax vaccine,atezolizumab and bevacizumab without UCPVax vaccine,objective response rate at 6 months,multicenter randomized phase II study,True,"Matches PICOS criteria: population, intervention, comparison, outcome, and study design align with target criteria."
72,patients with cirrhosis and HCC,TARE with (131)I-lipiodol,TACE,objective tumor response and survival,prospective clinical trial,False,Does not match PICOS criteria: intervention is not immune checkpoint inhibitors.
73,patients with unresectable hepatocellular carcinoma,palliative SBRT with camrelizumab,not specified,objective response rate and safety,phase 2 clinical trial,True,"Matches PICOS criteria: population, intervention, outcome, and study design align with target criteria. Comparison is not specified."
74,patients treated with TACE,CEUS Nonradiation TRA LI-RADS v2024,not specified,diagnostic performance of CEUS Nonradiation TRA LI-RADS,retrospective observational study,False,Does not match PICOS criteria: intervention is not immune checkpoint inhibitors and study design is not a randomized controlled trial.
75,patients with massive HCC,camrelizumab plus TACE,TACE alone,"clinical efficacy, adverse events, liver function, and biomarker levels",prospective study with random division into groups,True,"Matches PICOS criteria: population, intervention, comparison, outcome, and study design align with target criteria."
76,patients with MVI-positive HCC receiving marginal resection,postoperative adjuvant SBRT,surgery alone,disease-free survival and overall survival,single-centre randomised controlled trial,False,Does not match PICOS criteria: intervention is not immune checkpoint inhibitors.
77,patients with HCC recurrence who underwent curative surgery for HBV-related HCC,sequential therapy with ropeginterferon alfa-2b and nivolumab,not specified,"safety, tolerability, and inhibitory activity",Phase I clinical trial,False,Does not match PICOS criteria: study design is not a randomized controlled trial.
78,outpatient patients with HCC,standard oral cancer chemotherapy or targeted therapy,not specified,status of nonadherence and influencing factors,prospective observational study,False,Does not match PICOS criteria: intervention is not immune checkpoint inhibitors and study design is not a randomized controlled trial.
79,patients with advanced HCC in whom previous ICI therapy has failed,"SBRT, sintilimab and IBI305",not specified,"objective response rate, disease control rate, progression-free survival, overall survival, and safety","open-label, single-arm, single-centre, phase 2 trial",False,Does not match PICOS criteria: study design is not a randomized controlled trial.
80,patients with hepatocellular carcinoma,chemoembolization plus sorafenib,chemoembolization alone,"time-to-complete response, time-to-TACE progression, progression-free survival, overall survival",randomized controlled trial,False,"Intervention does not match ICIs, comparison and outcomes partially match"
81,patients with advanced or unresectable hepatocellular carcinoma,SBRT followed by nivolumab alone or nivolumab plus ipilimumab,nivolumab alone vs. nivolumab plus ipilimumab,"overall response rate, progression-free survival, overall survival",multicenter phase 1 randomized trial,True,Matches all PICOS criteria
82,patients with HBV-related HCC within the Milan criteria and with clinically significant PHT,partial hepatectomy,interventional treatment using ablation with or without pre-ablation TACE,"overall survival, recurrence-free survival",open-label randomized clinical trial,False,Intervention does not match ICIs
83,"adults with untreated, unresectable/metastatic HCC","BMS-986,205 in combination with nivolumab",not specified,"safety, tolerability, preliminary efficacy",Phase I/II study,False,"Comparison not specified, study design not RCT"
84,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with apatinib,DEB-TACE monotherapy,"progression-free survival, overall survival, objective response rates, disease control rates","randomized, prospective, multicenter phase III trial",False,Intervention does not match ICIs
85,HCC patients with PVTT,DEB-TACE,conventional TACE,"progression-free survival, overall survival, incidence of adverse events",randomized controlled trial,False,Intervention does not match ICIs
86,patients diagnosed with stage I-III HCC treated with TACE,combination stereotactic body radiotherapy or radiofrequency ablation,no additional liver-directed modality,progression-free survival,retrospective observational study,False,"Study design not RCT, intervention does not match ICIs"
87,advanced primary liver cancer patients with malignant ascites,intraperitoneal anti-PD-1 antibody,not specified,"safety, objective response rate, ascites control rate, overall survival",phase Ib study,False,"Comparison not specified, study design not RCT"
88,patients with a resectable single and small hepatitis B virus-related HCC predicted to have high risks of MVI,neoadjuvant intensity modulated radiation therapy,upfront surgery,"disease-free survival, overall survival, objective response rate",randomized,False,Intervention does not match ICIs
89,BCLC A patients with a solitary HCC from 4 to 7 cm,combination of TACE and SBRT,not specified,"best objective response rate, overall survival, progression-free survival",phase 2 trial,False,"Comparison not specified, intervention does not match ICIs"
90,patients with hepatocellular carcinoma,combination of tyrosine kinase inhibitors with anti-PD-L1 antibody,not specified,"overall response rate, progression-free survival, overall survival",phase 1b study,False,Does not specify comparison group or randomized controlled trial design.
91,patients with small hepatocellular carcinoma,novel radiofrequency ablation technique,not specified,"local tumor progression, intrahepatic remote recurrence, recurrence-free survival",prospective study,False,Does not specify comparison group or randomized controlled trial design.
92,hepatocellular carcinoma patients with inferior vena cava tumour thrombus,stereotactic body radiotherapy,not specified,"local control, overall survival",observational retrospective study,False,Does not specify comparison group or randomized controlled trial design.
93,treatment-naive patients with hepatocellular carcinoma,idarubicin-based transarterial chemoembolization,doxorubicin-based transarterial chemoembolization,"objective response rate, tumor responses, time-to-progression",randomized controlled trial,True,Matches all PICOS criteria.
94,locally advanced breast cancer patients,drug-eluting bead-transarterial chemoembolization combined with systemic chemotherapy,systemic chemotherapy alone,"overall response rate, pathological complete response",controlled study,False,Population does not match; study design not randomized controlled trial.
95,patients with hepatocellular carcinoma,"liver transplantation, transarterial chemoembolization",not specified,"hepatocellular carcinoma recurrence, treatment forms",retrospective observational study,False,Does not specify comparison group or randomized controlled trial design.
96,patients with advanced liver cancer,novel antisense oligonucleotide drug,not specified,"tolerability, safety",dose-escalation trial,False,Does not specify comparison group or randomized controlled trial design.
97,patients with hepatocellular carcinoma,pembrolizumab following transarterial chemoembolization,not specified,"safety, bioactivity",phase Ib study,False,Does not specify comparison group or randomized controlled trial design.
98,hepatocellular carcinoma patients,nomogram based on HCC-GRIm score,not specified,prognosis prediction,retrospective study,False,Does not specify comparison group or randomized controlled trial design.
99,patients with intermediate-stage hepatocellular carcinoma,dexamethasone and N-acetylcysteine combination,placebo,"prevention of post-embolization syndrome, liver decompensation",prospective study,False,Study design not specified as randomized controlled trial.
100,patients with hepatocellular carcinoma,PD-1 inhibitors,control group without PD-1 inhibitors,relapse-free survival,single-arm phase 2 trial,False,Study design is not a randomized controlled trial.
101,compensated cirrhosis patients with LS≥25 kPa,carvedilol,placebo,incidences of decompensated events,"randomized, double-blind, placebo-controlled, multicentre trial",False,Population does not match; not focused on hepatocellular carcinoma.
102,Barcelona Clinic Liver Cancer stage-C hepatocellular carcinoma patients,palliative stereotactic body radiation therapy,not specified,"local control, overall survival",observational retrospective study,False,Study design is not a randomized controlled trial and lacks a specified comparison.
103,patients with hepatocellular carcinoma or metastatic colorectal cancer,SIRT with (90)Y resin microspheres,not specified,safety and efficacy,"multicenter, single-arm, prospective, observational study",False,Study design is not a randomized controlled trial and lacks a specified comparison.
104,patients with unresectable hepatocellular carcinoma,DEB-TACE with CalliSpheres microspheres,conventional TACE,"treatment response, overall survival, progression-free survival",not specified,False,Study design is not specified as a randomized controlled trial.
105,patients with hepatocellular carcinoma,ultrasonic radiomics model,not specified,recurrence and differentiation of HCC,retrospective study,False,Study design is not a randomized controlled trial and lacks a specified comparison.
106,patients with hepatocellular carcinoma and portal vein tumor thrombus,radiotherapy prior to TACE,TACE followed with RT,overall survival,randomized controlled study,False,Intervention does not involve immune checkpoint inhibitors.
107,patients with advanced hepatocellular carcinoma,nivolumab and ipilimumab,not specified,antitumor response,virtual clinical trial using quantitative systems pharmacology,False,"Study design is a virtual clinical trial, not a randomized controlled trial."
108,patients underwent TACE intervention,Digital variance angiography,Digital subtraction angiography,contrast-to-noise ratio and image quality,retrospective study,False,Population and intervention do not match the specified criteria.
109,patients with advanced hepatocellular carcinoma,GT90001 plus nivolumab,not specified,safety and anti-tumor activity,phase 1b/2 study,False,Study design is not a randomized controlled trial.
110,patients with metastatic non-small cell lung cancer,novel systemic treatments,control arm without novel treatments,"quality of life, progression-free survival, overall survival",randomized controlled trial,False,Population does not match; intervention not specified as ICIs; outcomes include QoL not matching target
111,patients with unresectable hepatocellular carcinoma,TACE combined with TKI and camrelizumab,not specified,"progression-free survival, objective response rate",not specified,False,"Intervention includes TKI and camrelizumab, not solely ICIs; comparison and study design not specified"
112,patients with unresectable hepatocellular carcinoma,TACE with dicycloplatin alone or plus epirubicin,epirubicin alone,"objective response rate, disease control rate, progression-free survival","randomized, open-label, phase II trial",False,"Intervention not ICIs; study design is phase II, not phase III RCT"
113,patients with unresectable hepatocellular carcinoma,DEB-TACE with doxorubicin-loaded CalliSpheres microspheres,cTACE with doxorubicin-lipiodol emulsion,"clinical response rate, overall survival, progression-free survival",randomized controlled trial,False,Intervention not ICIs; outcomes include clinical response rate not matching target
114,patients with hepatocellular carcinoma,DEB-TACE,not specified,acute liver function deterioration,not specified,False,Intervention not ICIs; outcome not matching target; study design not specified
115,patients with PD-L1-positive advanced gastric/gastroesophageal junction cancer,pembrolizumab,paclitaxel,"overall survival, progression-free survival, objective response rate","randomized, controlled, phase III trial",False,Population does not match; intervention is ICI but for different cancer type
116,patients with hepatocellular carcinoma tumors sized 3.5-7 cm,sorafenib prior to RFA,placebo,"size of ablation zone, RFA thermal parameters","randomized, double-blind, placebo-controlled phase II trial",False,"Intervention not ICIs; study design is phase II, not phase III RCT"
117,patients with unresectable early- and intermediate-stage hepatocellular carcinoma,tirapazamine in TACE,not specified,"safety, complete response rate, partial response rate","phase I, 3 + 3 dose-escalation study",False,"Intervention not ICIs; study design is phase I, not phase III RCT"
118,patients with hepatocellular carcinoma,yttrium-90 resin transarterial radioembolization,TACE-naive participants,"overall survival, best response, toxicities","prospective, observational study",False,"Intervention not ICIs; study design is observational, not RCT"
119,patients with unresectable Barcelona Clinic Liver Cancer stage B HCC Child Pugh A,TACE followed by SBRT,TACE alone,"local control, progression-free survival, overall survival, toxicity",randomized,False,Intervention not ICIs; study design not specified as phase III RCT
120,patients with high-risk recurrence factors after curative resection of HCC,Cidan Capsule combined with adjuvant TACE,TACE without Cidan Capsule,"disease-free survival, tumor recurrence rate, overall survival",randomized controlled trial,False,Population does not specifically mention hepatocellular carcinoma patients treated with ICIs.
121,patients with HCCs >3 cm,combination therapy using TACE with MWA,MWA monotherapy,"local tumor progression, tumor control rate, overall survival",retrospective observational study,False,Study design is not a randomized controlled trial and does not involve ICIs.
122,advanced PHC patients,TACE combined with radioactive iodine implantation therapy,TACE alone,"tumor lesion length, serum AFP, CT perfusion parameters, survival time",randomized controlled trial,False,Intervention does not involve ICIs.
123,patients with large or huge HCC,CBATO-TACE,cTACE,"progression-free survival, overall survival, treatment response",randomized controlled trial,False,Intervention does not involve ICIs.
124,patients with virologically suppressed HBV-compensated cirrhosis and small/medium EV,carvedilol plus NUC,NUC alone,"progression rate of EV, liver-related events",randomized controlled trial,False,Population and intervention do not match the specified criteria.
125,patients with intermediate-stage HCC beyond the Up-to-7 criteria,LEN-TACE sequential therapy,not specified,"resection rate, objective response rate, overall survival, recurrence-free survival","single-arm, prospective clinical trial",False,Study design is not a randomized controlled trial and does not involve ICIs.
126,patients with HCC beyond the Milan criteria treated by TACE after TIPS,TACE,not specified,overall survival,retrospective study,False,Study design is not a randomized controlled trial and does not involve ICIs.
127,patients with BCLC stage-B HCC,TACE combined with atezolizumab plus bevacizumab,not specified,"objective response rate, overall survival, disease control rate, progression-free survival, time-to-progression","open-label, single-arm phase II clinical trial",False,Study design is not a randomized controlled trial.
128,patients with early hepatocellular carcinoma,radiofrequency ablation,percutaneous ethanol injection,"cost-effectiveness, complete response rate, complication rate",prospective single-center randomized trial,False,Population and intervention do not match the specified criteria.
129,patients with locally advanced or metastatic HCC,BLU-554 in combination with CS1001,not specified,objective response rate,Phase Ib/II trial,False,Study design is not a randomized controlled trial.
130,patients with refractory MSS CLM,VB-111 and nivolumab,not specified,overall response rate and safety/tolerability,phase II study,False,Population does not match hepatocellular carcinoma; no specified comparison group.
131,patients with unresectable HCC,apatinib combined with IMRT,not specified,maximum tolerated dose and treatment response,dose-escalation design,False,"Population matches, but no specified comparison group and outcomes do not include survival or response rate."
132,patients with intermediate stage HCC after incomplete response to TAE/TACE,SBRT,standard TAE/TACE,"1-year local control, progression-free survival, overall survival",randomized controlled trial,False,"Population and study design match, but intervention is not immune checkpoint inhibitors."
133,HCC patients post-resection,TACE and HAIC,no other treatment,impact on liver function,not specified,False,"Population matches, but intervention is not immune checkpoint inhibitors and outcomes do not include survival or response rate."
134,HCV-infected patients,sofosbuvir/velpatasvir or glecaprevir/pibrentasvir,not specified,safety and sustained virological response,observational study,False,Population does not match hepatocellular carcinoma; intervention is not immune checkpoint inhibitors.
135,advanced HCC patients with variceal bleeding,TIPS,endoscopic + β-blocker therapy,variceal rebleeding and overall survival,randomized controlled trial,False,"Population matches, but intervention is not immune checkpoint inhibitors."
136,patients with metastatic colorectal cancer to the liver,IRI-HEP-TACE,not specified,"overall survival, progression-free survival, objective response rate",prospective study,False,Population does not match hepatocellular carcinoma; intervention is not immune checkpoint inhibitors.
137,treatment-naïve HBV-related decompensated patients,antiviral treatment,not specified,recompensation and long-term prognosis,retrospective multi-center study,False,Population does not match hepatocellular carcinoma; intervention is not immune checkpoint inhibitors.
138,liver cancer patients after TACE,individualized nutritional intervention,routine dietary intervention,"nutritional status, liver function status, incidence of complications",randomized controlled trial,False,"Population matches, but intervention is not immune checkpoint inhibitors and outcomes do not include survival or response rate."
139,HCC patients treated with ICIs,"continuation of ICI, treatment switching to TKIs, cessation of anticancer therapy",not specified,post-progression survival,not specified,False,"Population and intervention match, but no specified comparison group and study design is not a randomized controlled trial."
140,patients with beyond-the-Milan criteria HCC,combination TACE and RFA therapy,TACE monotherapy,"1-month tumour response, progression-free survival, overall response rate, overall survival",randomized controlled trial,False,"Population and study design match, but intervention and comparison do not involve immune checkpoint inhibitors."
141,patients with advanced or metastatic HCC,"itacitinib, a selective JAK1 inhibitor",not specified,safety and efficacy,Phase Ib study,False,"Population matches, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison or outcome related to survival or response rate."
142,patients with untreated advanced HCC,anlotinib alone or combined with S-1,not specified,"objective response rate, disease control rate, progression-free survival, overall survival",randomized,False,"Population and study design partially match, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison."
143,patients with HCC previously treated with molecular targeted agents,atezolizumab plus bevacizumab,not specified,treatment response,not specified,False,"Population and intervention partially match, but there is no specified comparison or study design, and outcome is not directly related to survival or response rate."
144,HCC Egyptian patients,Transarterial Chemoembolization (TACE),not specified,response to TACE,prospective cohort study,False,"Population matches, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison or outcome related to survival or response rate."
145,hepatocellular carcinoma patients,real-time image-guided radiation therapy,not specified,feasibility of using x-ray images,observational study,False,"Population matches, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison or outcome related to survival or response rate."
146,CNLC-IIIb stage HCC patients,hepatectomy in combination with apatinib and camrelizumab,not specified,patient mortality,multicentre phase II trial,False,"Population and intervention partially match, but there is no specified comparison, and outcome is not directly related to survival or response rate."
147,patients with HCC,multipolar radiofrequency ablation (RFA) system,not specified,therapeutic efficacy and safety,retrospective cohort study,False,"Population matches, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison or outcome related to survival or response rate."
148,patients who underwent TACE,real-time radiation dosimetry,not specified,occupational dose of the medical staff,retrospective observational study,False,"Population matches, but intervention is not an immune checkpoint inhibitor, and there is no specified comparison or outcome related to survival or response rate."
149,patients with unresectable hepatocellular carcinoma,transarterial chemoembolization combined with programmed cell death protein-1 inhibitors plus lenvatinib,programmed cell death protein-1 inhibitors plus lenvatinib,"objective response rate, overall survival, progression-free survival","observational, retrospective, cohort study",False,"Population, intervention, and comparison partially match, but study design is not a randomized controlled trial, and intervention includes more than just immune checkpoint inhibitors."
150,patients with hepatocellular carcinoma,not specified,not specified,survival outcomes,retrospective study,False,"Does not specify intervention with ICIs or comparison, and is not a randomized controlled trial."
151,patients with hepatocellular carcinoma and bile duct tumor thrombus,surgical treatment,not specified,recurrence rates,retrospective study,False,"Does not involve ICIs, lacks a specified comparison, and is not a randomized controlled trial."
152,"patients with liver, lung, and kidney tumors",high-power microwave ablation,not specified,"technical success, safety, and effectiveness",retrospective observational study,False,"Does not focus on hepatocellular carcinoma exclusively, lacks ICIs, and is not a randomized controlled trial."
153,patients with hepatocellular carcinoma undergoing TACE,preoperative interview and prospective nursing,routine nursing care,"psychological stress reactions, pain, complications, and satisfaction",randomized controlled trial,False,Does not involve ICIs and focuses on nursing interventions rather than ICIs.
154,patients with small hepatocellular carcinoma,radiofrequency ablation with a novel electrode system,not specified,technical efficacy and complications,"prospective, single-center clinical trial",False,Does not involve ICIs and lacks a specified comparison group.
155,patients with HBV-related primary liver cancer undergoing TACE,TACE,not specified,severe abdominal pain post-TACE,retrospective study,False,Does not involve ICIs and is not a randomized controlled trial.
156,patients with liver cancer undergoing RFA,RFA,not specified,relapse-free survival and overall survival,retrospective study,False,Does not involve ICIs and is not a randomized controlled trial.
157,patients with hepatocellular carcinoma,"RFA, TACE, TARE, and Sorafenib",not specified,recurrence-free rates and survival rates,retrospective observational study,False,Does not involve ICIs and is not a randomized controlled trial.
158,patients with hepatocellular carcinoma undergoing TACE,TACE,not specified,progression-free survival and TACE treatment response,prospective single-center observational study,False,Does not involve ICIs and is not a randomized controlled trial.
159,patients with advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,not specified,not specified,discussion of preclinical rationale and study designs,False,Focuses on the rationale and study designs for combining MKIs with ICIs but does not present a randomized controlled trial with specified outcomes.
160,patients with advanced/metastatic solid tumors including hepatocellular carcinoma,CS1002 (anti-CTLA-4 monoclonal antibody) as monotherapy and in combination with CS1003 (anti-PD-1 monoclonal antibody),not specified,safety profile and antitumor activities,phase 1 study including dose-escalation and expansion,False,"Population includes various solid tumors, not exclusively hepatocellular carcinoma. No clear comparison group specified. Outcomes focus on safety and antitumor activities, not specifically survival or response rates."
161,"HCC patients with a solitary lesion 2-5 cm, or a maximum of 3 lesions of ≤3 cm each",holmium-166 microspheres administered after radiofrequency ablation,not specified,"biodistribution of holmium-166, toxicity, local recurrence, disease-free and overall survival","multicentre, prospective, dose-escalation study",False,Population matches but intervention is not immune checkpoint inhibitors. No comparison group specified. Study design is not a randomized controlled trial.
162,HCC patients,neoadjuvant SBRT plus PD-1 (tislelizumab) prior to hepatic resection,not specified,"delay of surgery, tumour response, safety, tolerability, disease-free survival, and overall survival",phase Ib clinical trial,False,Population and intervention match but no comparison group specified. Study design is not a randomized controlled trial.
163,HCC patients treated with DEB-TACE,Drug-Eluting Beads (DEB)-TACE,not specified,overall survival,"observational, retrospective, unicentric study",False,Population matches but intervention is not immune checkpoint inhibitors. No comparison group specified. Study design is not a randomized controlled trial.
164,HCC patients referred for TACE,pre-TACE three dimensional (3D) CT angiography,non-selective digital subtraction angiography (DSA),detection of HCC feeding vessels,prospective study,False,Population matches but intervention is not immune checkpoint inhibitors. Study design is not a randomized controlled trial.
165,HCC patients undergoing TACE,transradial access (TRA) vs transfemoral access (TFA),TRA vs TFA,"patient satisfaction, procedural variables, and safety",randomized allocation,False,"Population matches but intervention is not immune checkpoint inhibitors. Outcomes focus on patient satisfaction and procedural variables, not survival or response rates."
166,unresectable hepatocellular carcinoma (uHCC) patients,"lenvatinib, programmed death-1 inhibitors plus transcatheter arterial chemoembolization",not specified,"overall survival, progression-free survival, early tumor shrinkage",prospective observational study,False,Population and intervention partially match but no comparison group specified. Study design is not a randomized controlled trial.
167,HCC patients contraindicated for hepatectomy and RFA,HIFU alone or combined with TACE,not specified,"local control rate, progression-free survival, overall survival",not specified,False,Population matches but intervention is not immune checkpoint inhibitors. No comparison group specified. Study design not specified.
168,unresectable hepatocellular carcinoma patients,TACE combined with (131)I-metuximab,TACE alone,"overall tumor recurrence, overall survival","prospective nonrandomized, multicenter clinical trial",False,Population and comparison match but intervention is not immune checkpoint inhibitors. Study design is not a randomized controlled trial.
169,dogs with nonresectable hepatic carcinoma,drug-eluting bead transarterial-chemoembolization (DEB-TACE),not specified,median survival time,"prospective, single-arm clinical trial",False,Population is not human patients with hepatocellular carcinoma. Intervention is not immune checkpoint inhibitors. No comparison group specified. Study design is not a randomized controlled trial.
170,patients with primary liver cancer,Fuzheng Jiedu Xiaoji formula plus chemoembolization,chemoembolization alone,"disease control rate, liver biochemistry, liver function index, multidrug resistance-associated indicators",randomized controlled trial,False,Population does not match hepatocellular carcinoma; intervention does not involve immune checkpoint inhibitors.
171,patients with hepatocellular carcinoma,conventional transarterial chemoembolization,not specified,overall survival,randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors; comparison not specified.
172,HCC patients with portal vein tumor thrombus,"liver resection, transarterial chemoembolization, sorafenib",not specified,overall survival,randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors; comparison not specified.
173,HCC patients with portal vein tumor thrombus,Gamma knife radiosurgery,transcatheter arterial chemoembolization,overall survival,retrospective study,False,Intervention does not involve immune checkpoint inhibitors; study design is not a randomized controlled trial.
174,HCC patients with low platelet counts,Lusutrombopag,not specified,"platelet count elevation, prevention of platelet transfusions",not specified,False,Intervention does not involve immune checkpoint inhibitors; comparison and study design not specified.
175,patients with unresectable hepatocellular carcinoma,"celecoxib, parecoxib, oxycodone",not specified,"pain scores, pain intensity, adverse events","randomized, paralleled trial",False,Intervention does not involve immune checkpoint inhibitors; comparison not specified.
176,adults with intermediate-stage HCC,TACE with idarubicin,not specified,"pharmacokinetics, antitumour effects, safety",single-centre clinical trial,False,Intervention does not involve immune checkpoint inhibitors; comparison not specified.
177,early non-resectable patients with HCC,laparoscopic microwave ablation,"trans-arterial chemoembolization, percutaneous radiofrequency ablation","overall survival, HCC-related death",retrospective multicenter observational study,False,Intervention does not involve immune checkpoint inhibitors; study design is not a randomized controlled trial.
178,patients with stage B or stage C liver cancer,"transcatheter arterial chemoembolization, percutaneous transhepatic varices embolization",not specified,"initial occurrence time of hemorrhage, recurrence time of hemorrhage, liver function, TACE frequency, TACE type, tumor control",retrospective study,False,Intervention does not involve immune checkpoint inhibitors; study design is not a randomized controlled trial.
179,patients with HCC,balloon-occluded alternate infusions of cisplatin and gelatin particles in transarterial chemoembolization,not specified,"safety, objective response rate",multicenter prospective study,False,Intervention does not involve immune checkpoint inhibitors; comparison not specified.
180,patients with standard chemotherapy refractory mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC),pexastimogene devacirepvec (PexaVec) plus durvalumab with and without tremelimumab,not specified,"safety, feasibility, progression-free survival (PFS), overall survival",phase I/II trial,False,Population does not match hepatocellular carcinoma; intervention includes ICIs but not solely focused on them; no clear comparison group; outcomes include survival but not specifically response rate; study design is not a randomized controlled trial.
181,patients with advanced digestive tract cancer including hepatocellular carcinoma (HCC),PD-1 inhibitors plus antiangiogenic agents,not specified,"response rate, progression-free survival (PFS), overall survival (OS)",observational retrospective study,False,Population includes HCC but not exclusively; intervention includes ICIs but also antiangiogenic agents; no clear comparison group; outcomes include survival and response rate; study design is not a randomized controlled trial.
182,patients with HCC at BCLC substage B2,Lenvatinib (LEN),not specified,"overall survival, progression-free survival, objective response rates",prospective observational study,False,Population matches; intervention is not an ICI; no clear comparison group; outcomes include survival and response rate; study design is not a randomized controlled trial.
183,patients who have undergone initial hepatectomy for HCC with risk factors for recurrence,peripheral blood CD34(+) stem cell-derived NK cell infusion,not specified,"safety, survival, immune response","open-label, single-arm, single-centre phase I study",False,Population matches; intervention is not an ICI; no clear comparison group; outcomes include survival but not specifically response rate; study design is not a randomized controlled trial.
184,participants with Child Pugh A unresectable hepatocellular carcinoma,intravenous atezolizumab,with/without the Roche DPM Module,participant-reported Total Symptom Interference Score,"interventional, open-label, multicountry platform study",False,"Population matches; intervention includes an ICI; comparison is with/without a digital patient monitoring tool, not a treatment without ICIs or placebo; outcomes do not include survival or response rate; study design is not a randomized controlled trial."
185,hepatocellular carcinoma (HCC) patients,not specified,not specified,"prognostic prediction, immunotherapeutic strategies",not specified,False,Population matches; intervention not specified; no comparison group; outcomes not related to survival or response rate; study design not specified.
186,advanced HCC patients,pegylated arginase (PEG-BCT-100) in combination with chemotherapy (oxaliplatin and capecitabine),not specified,"safety, efficacy, time to progression (TTP), progression-free survival (PFS), overall survival (OS)",single centre phase 1 trial,False,Population matches; intervention is not an ICI; no clear comparison group; outcomes include survival but not specifically response rate; study design is not a randomized controlled trial.
187,patients with immunotherapy-naive solid tumors including hepatocellular carcinoma (HCC),isatuximab plus atezolizumab,not specified,"safety, activity, overall response rate, progression-free survival rate at 6 months",phase I/II study,False,Population includes HCC but not exclusively; intervention includes an ICI but also isatuximab; no clear comparison group; outcomes include survival and response rate; study design is not a randomized controlled trial.
188,patients with unresectable HCC after TACE failure,TAE therapy with biweekly iNKT cell infusion,TAE therapy without iNKT cell infusion,"progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL)","open-label, randomized, controlled trial",False,"Population matches; intervention is not an ICI; comparison is with/without iNKT cell infusion, not a treatment without ICIs or placebo; outcomes include survival and response rate; study design is a randomized controlled trial but intervention does not match."
189,patients with liver tumor planned for microwave ablation (MWA) treatment,pre-emptive erector spinae plane block (ESPB),no ESPB,"opioid consumption, numeric rating scale (NRS) scores for pain",randomized study,False,"Population does not match hepatocellular carcinoma; intervention is not an ICI; comparison is with/without ESPB, not a treatment without ICIs or placebo; outcomes not related to survival or response rate; study design is randomized but intervention does not match."
190,patients with hepatocellular carcinoma,preoperative gadoxetic acid-enhanced MRI,not specified,predict outcomes of immunotherapy,retrospective study,False,The study does not involve immune checkpoint inhibitors or a randomized controlled trial design.
191,patients with hepatocellular carcinoma,sorafenib,not specified,treatment patterns and outcomes,"retrospective, single-arm, observational study",False,The study does not involve immune checkpoint inhibitors or a randomized controlled trial design.
192,patients with stage III-IV lung cancer,DEB-TACE with pirarubicin-loaded CB,not specified,safety and efficacy,not specified,False,"The population is not patients with hepatocellular carcinoma, and the study does not involve immune checkpoint inhibitors or a randomized controlled trial design."
193,pediatric hepatoblastoma patients,HIFU combined with TACE,TACE alone,"immune function, survival, treatment side effects",comparative study,False,"The population is pediatric hepatoblastoma patients, not hepatocellular carcinoma, and the study does not involve immune checkpoint inhibitors or a randomized controlled trial design."
194,patients with hepatocellular carcinoma,curative-intent resection or ablation,not specified,overall survival,retrospective observational study,False,The study does not involve immune checkpoint inhibitors or a randomized controlled trial design.
196,UICC7 Stage IIIA and IIIB potentially resectable HCC patients,preoperative chemotherapy,upfront resection,overall survival,phase II clinical trial,False,The study does not involve immune checkpoint inhibitors or a randomized controlled trial design.
197,patients with hepatocellular carcinoma,IRE,RFA,progress-free survival and overall survival,randomized controlled clinical trial,False,The intervention is not immune checkpoint inhibitors.
198,patients with hepatocellular carcinoma,TACE,different patients' positions via TRA or TFA,radiation dose received by the operator,randomized study,False,The study does not involve immune checkpoint inhibitors or a randomized controlled trial design focused on survival or response rates.
199,patients with liver cancer undergoing TACE,3M2H-PARP,standard care,effectiveness and feasibility of the programme,randomized controlled trial,False,"The population is not specifically patients with hepatocellular carcinoma, and the intervention is not immune checkpoint inhibitors."
195,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
200,patients with hepatoblastomas,not specified,not specified,overall survival rate,retrospective analysis,False,Population does not match hepatocellular carcinoma; no intervention or comparison specified; study design is not a randomized controlled trial.
201,patients with hepatocellular carcinoma,transradial access in c-TACE,transfemoral access in c-TACE,"operators radiations exposure, patients comfort, technical success, vascular access complications",multicenter prospective study,False,Population matches; intervention and comparison are specified but not related to ICIs; outcomes do not include survival or response rate; study design is not a randomized controlled trial.
202,patients with systemic lupus erythematosus and non-SLE autoimmune-mediated rheumatic diseases,not specified,not specified,sensitivity and specificity of classification criteria,prospective and retrospective observational cohort study,False,Population does not match hepatocellular carcinoma; no intervention or comparison specified; outcomes and study design do not match the criteria.
204,patients with primary and secondary liver tumors,novel ablation confirmation method,visual inspection and anatomical landmarks-based quantitative measurements,"minimal ablative margin, 2-year LTP-free survival, complication rates, quality of life, liver function, other oncological outcomes","single-center, randomized, phase II, intent-to-treat trial",False,Population partially matches; intervention and comparison are specified but not related to ICIs; outcomes include survival but not response rate; study design is a randomized controlled trial but not focused on ICIs.
205,patients with hepatocellular carcinoma,clinical decision support system,handbook only,"patient-centered caring attitude, pain management barrier identification, comfort care competence, symptom interference",randomized controlled trial,False,Population matches; intervention and comparison are specified but not related to ICIs; outcomes do not include survival or response rate; study design is a randomized controlled trial but not focused on ICIs.
203,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
